Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.
The agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
The grant is the fifth consecutive five-year grant the Alzheimer Disease Center has received from NIH to support research to understand the causes and potential treatments for Alzheimer’s and other forms of dementia.
American Senior Communities says Auguste's Cottage at Harrison Terrace on the east side of Indianapolis already has 90 residents.
Analysts have eyes on trial data for drug that could be a game-changer for the company.
Remaining grant money will be invested to beef up the infrastructure of the Indiana Network for Patient Care, a health information exchange operated by the Indianapolis-based Regenstrief Institute.
Eli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.
